HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ST2825

structure in first source

Networked: 15 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - ST2825: 15
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Spiro Compounds: 2
      - ST2825: 15
Polycyclic Compounds: 6
- Spiro Compounds: 2
  - ST2825: 15

Experts

1.	Du, Guan-Hua: 1 article (05/2022)
2.	Liu, Dong-Ni: 1 article (05/2022)
3.	Liu, Man: 1 article (05/2022)
4.	Shang, Yu-Fu: 1 article (05/2022)
5.	Wang, Yue-Hua: 1 article (05/2022)
6.	Zhang, Shan-Shan: 1 article (05/2022)
7.	Cui, Zhijuan: 1 article (01/2022)
8.	Deng, Yuankun: 1 article (01/2022)
9.	Liao, Simeng: 1 article (01/2022)
10.	Qi, Ming: 1 article (01/2022)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/2022 - "In mouse model, inhibition of MyD88 using specific inhibitor ST2825 followed by PQ treatment effectively ameliorates weight loss (~4% increment), decreased food intake (~92% increment), gastrocnemius and soleus loss (~24% and ~20% increment, respectively), and intestinal oxidative stress in an autophagy dependent manner (P < 0.01). "
2.	Brain Edema (Cerebral Edema) 01/01/2016 - "Intracerebroventricular (ICV) injection of high concentration (20μg/μL) ST2825 (15min post TBI) attenuated the development of TBI in mice, markedly improved neurological function and reduced brain edema. "
3.	Inflammation (Inflammations) 01/01/2021 - "This study aimed to identify the effect of the MyD88 dimerization inhibitor, ST2825, as a modulator of pathogenic gene expression signatures and systemic inflammation in disease-modifying antirheumatic drugs (DMARDs)-naïve RA patients. " 01/01/2023 - "Concurrently, ST2825 also downregulated the genes encoding for pain, inflammation, and joint catabolism mediators while upregulating the genes required for the translocation of nuclear proteins into the mitochondria and members of the mitochondrial respiratory complex 1. Finally, we demonstrated that ST2825 inhibited the invasiveness of RA SFs, by showing decreased migration of LPS-treated RA SFs in spheroid cultures. "
4.	Hepatocellular Carcinoma (Hepatoma) 03/04/2016 - "Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells." 03/04/2016 - "The purpose of this study was to investigate the effect of ST2825, an inhibitor of myeloid differentiation factor 88 (MyD88), on the proliferation and apoptosis of human hepatocellular carcinoma (HCC) cells as well as the potential mechanism and clinical significance of ST2825 in the treatment of HCC. "
5.	Neoplasms (Cancer) 01/01/2021 - "Treatment with the MyD88 inhibitor ST2825 also suppressed the growth of the intestinal tumor-derived organoids. " 11/01/2019 - "ST2825 has the potential for clinical use in patients with L265P DLBCL, and other B‑cell neoplasms driven by activated MYD88 signaling." 11/01/2017 - "ST2825 may be a novel drug targeting not only B-lymphoid malignancies with MYD88 mutations, but also lymphoma and leukaemia with wild-type MYD88."

Related Drugs and Biologics

1.	Myeloid Differentiation Factor 88
2.	Antirheumatic Agents (DMARD)
3.	Small Interfering RNA (siRNA)
4.	Inflammation Mediators
5.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
6.	Pilocarpine (Ocusert)
7.	Nuclear Proteins (Protein, Nuclear)
8.	Lipopolysaccharides
9.	NF-kappaB-Inducing Kinase
10.	Agammaglobulinaemia Tyrosine Kinase

Related Therapies and Procedures

1.	Transplantation